Distinguished in Age-Related Macular Degeneration (ARMD)

Hidenori Takahashi

Suita, JP 
Distinguished in Age-Related Macular Degeneration (ARMD)
Suita, JP 
OverviewLocationsClinical Research

Overview

Hidenori Takahashi practices in Suita, Japan. Takahashi is rated as a Distinguished expert by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). Their top areas of expertise are Pancreatic Cancer, Age-Related Macular Degeneration (ARMD), Cholangiocarcinoma (Bile Duct Cancer), Pancreatectomy, and Corneal Transplant.

Their clinical research consists of co-authoring 487 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 28 articles in the study of Age-Related Macular Degeneration (ARMD).

Locations

Suita, Japan
Other Locations
Higashi, 1408522, Japan
Tsukuba, 3058577, Japan
Osaka, Japan
Kyoto, 6048511, Japan
Tokyo, Japan
Yamaguchi, Japan
Ube, Japan
Hino, 1918512, Japan
Tochigi, Japan
Shimotsuke, Japan
Chuo, 5418567, Japan
Tsuchiura, 3000028, Japan
Higashioi, 1408522, Japan
Asahi, Japan
Kumamoto, Japan
Sapporo, Japan
Utsunomiya, Japan
Kodaira, Japan
Shinjuku, Japan
Hongo, 1138655, Japan
Musashino, Japan
Minato, 1088477, Japan
Yokohama, 2238522, Japan
Showa, Japan
Shinjiku, Japan
Ginowan, Japan
Funabashi, 2748510, Japan
Nakamichi, 5370025, Japan
Fukuoka, 8100001, Japan
Course Of Medical And Dental Sciences, Nagasaki, Japan
Yushima, 1138519, Japan
Sendai, 9808574, Japan
Fukushima, Japan
Kobe, 6500017, Japan
Isehara, 2591193, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

487 Total Publications

Response to the letter to the editor: "Refining the prognostic utility of CA19-9 in neoadjuvant therapy for pancreatic cancer: Emphasizing serial monitoring and subgroup differentiation".
Response to the letter to the editor: "Refining the prognostic utility of CA19-9 in neoadjuvant therapy for pancreatic cancer: Emphasizing serial monitoring and subgroup differentiation".
Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Published: September 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Takahashi's expertise for a condition
ConditionClose
View All 22 Advanced Conditions
View All 90 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile